Congo Approves Experimental Ebola Treatments by Gilead, Mapp, Toyama Chemical and Regeneron

 Congo Approves Experimental Ebola Treatments by Gilead, Mapp, Toyama Chemical and Regeneron

Congo Approves Experimental Ebola Treatments by Gilead, Mapp, Toyama Chemical and Regeneron

Shots:
  • Congo approves experimental Ebola treatments including Remdesivir by Gilead Sciences; ZMapp by Mapp Pharmaceutical; Favipiravir by Toyama and Regn3450, Regn3471, Regn3479 by Regeneron Pharmaceuticals
  • Health authorities has approved these experimental treatments, as the Ebola epidemic continues to spread
  •   Total number of death are 59 and confirmed cases to 75 since last month, with ~ 11,000 in West Africa from 2013-2016, 33 people in northwest

Click here to read full press release/ article | Ref: Reuters | Image:  Reuters

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post